Kaiser Permanente Ventures is joined leading the series D round by venture firm Redmile Group.
Kaiser Permanente’s corporate venturing unit has helped TriVascular, a US-based aortic disease treatment company, raise a $60m round.
Kaiser Permanente Ventures was joined leading the series D round by venture firm Redmile Group.
Venture investor New Enterprise Associates, Delphi Ventures, MPM Capital, Kearny Venture Partners and Pinnacle Ventures also took part in the round.
Sam Brasch, a director at Kaiser Permanente Ventures, will join TriVascular’s board.
Trivascular said it would use the funds to seek a US Premarket…
